This federal contract award, valued at $233,343,418.86, was granted to Hoffmann-La Roche Inc. by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency. The contract is for the "Combating Multi-Drug Resistance and Addressing Emerging Bacterial Threats: Discovery, Clinical Development" program. It is a definitive, cost-no-fee contract with a performance period ending on December 31, 2026. The contract does not have a set-aside designation.
Generated 2/21/25, 9:50 AM